Corporate influences on epidemiology

International Journal of Epidemiology

Volumn 37, Issue 1, 2008, Pages 46-53

  Pearce, Neil ^a  

^a MASSEY UNIVERSITY   (New Zealand)

Author keywords

Epidemiologic methods; Epidemiology; Ethics

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ASCORBIC ACID; BENZENE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA CAROTENE; CALCIUM CHANNEL BLOCKING AGENT; CHROMIUM; DIETHYLSTILBESTROL; DIOXIN; ESTROGEN; FENOTEROL; ORAL CONTRACEPTIVE AGENT; RECOMBINANT ERYTHROPOIETIN; ROFECOXIB;

DECISION MAKING; EPIDEMIOLOGY; ETHICS; PHARMACEUTICAL INDUSTRY; SCIENCE AND TECHNOLOGY;

ADVISORY COMMITTEE; ARTICLE; ASTHMA; CANCER RISK; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COLON CANCER; CONSULTATION; DECISION MAKING; DIETARY FIBER; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MARKETING; DRUG SAFETY; ENDOMETRIUM CANCER; ENVIRONMENTAL EXPOSURE; EPIDEMIOLOGICAL DATA; EXPERT WITNESS; FUNDING; HEALTH HAZARD; HOME CARE; HORMONE SUBSTITUTION; HUMAN; LICENSING; LIFESTYLE; LUNG CANCER; MEDICAL ETHICS; MEDICAL RESEARCH; MEDICAL SOCIETY; PATIENT CARE; PHARMACOEPIDEMIOLOGY; POLICY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH; PUERPERAL INFECTION; RELIABILITY; RESEARCH ETHICS; REYE SYNDROME; SMOKING; TAMPON; THROMBOEMBOLISM; TOXIC SHOCK SYNDROME; VAGINA CANCER; VITAMIN INTAKE; WATER CONTAMINATION;

CONFLICT OF INTEREST; EPIDEMIOLOGIC METHODS; EPIDEMIOLOGY; FEMALE; HUMANS; INTERPROFESSIONAL RELATIONS; MALE; NEW ZEALAND; PHYSICIAN'S PRACTICE PATTERNS; PROFESSIONAL CORPORATIONS;

EID: 38949106500     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dym270     Document Type: Article

References (67)

1. Pearce N, Beasley R, Crane J, Burgess C, Jackson R. End of the New Zealand asthma mortality epidemic. Lancet 1995;345:41-44.
2. Anon. 'b-2 agonists' in asthma: Relief, prevention, morbidity. Lancet 1990;336:1391-96.
3. Anon. The 'b-agonist' dilemma. N Engl J Med 1992;326:560-61.
4. Anon. 'b-agonists' and asthma. Lancet 1992;339:422.
5. Pearce N. Adverse reactions, social responses: A tale of two asthma mortality epidemics. In: Davis P (ed.). Contested Ground: Public Purpose and Private Interest in the Regulation of Prescription Drugs. New York: Oxford University Press, 1996. pp. 57-75.
6. Pearce N. Adverse reactions: The fenoterol story. Auckland: Auckland University Press, 2007.
7. Stolley PD. A public health perspective from academia. In: Strom BL (ed.). Pharmacoepidemiology. New York: Churchill Livingstone, 1989.
8. Tong S, Olsen J. the threat to scientific integrity in environmental and occupational medicine, Occup Environ Med 2005;62:843-46.
9. Stolley PD. When genius errs: Fisher, R.A. and the lung cancer controversy. Am J Epidemiol 1991;133:416-25.
10. Doll R, Bradford Hill A. Smoking and carcinoma of the lung: Preliminary report. Br Med J 1950;2:739-48.
11. Wynder EL, Graham EA. Tobacco smoking as a possible etiologic factor in bronchiogenic carcinoma: A study of 684 proved cases. JAMA 1950; 143:329-36.
12. Chapman S. The hot air on passive smoking. Br Med J 1998;945.
13. Francis JA, Shea AK, Samet JM. Challenging the epidemiologic evidence on passive smoking: Tactics of tobacco industry expert witnesses. Tob Control 2006;15:68-76.
14. Ong EK, Glantz SA. Constructing "sound science and "good epidemiology": Tobacco, lawyers, and public relations firms. Am J Public Health 2001;91:1749-57.
15. Savitz DA, Greenland S, Stolley PD, Kelsey JL. Scientific standards of criticism: A reaction to "Scientific standards in epidemiologic studies of the menace of daily life" by A.R. Feinstein. Epidemiology 1990;1:78-83.
16. Greenland S. Science versus advocacy: The challenge of Dr Feinstein. Epidemiology 1990;1:64-72.
17. Davey Smith G, Ebrahim S. Epidemiology - is it time to call it a day? Int J Epidemiol 2001;301:1-11.
18. Femstein AR. Scientific standards in epidemiologic studies of the menace of daily life. Science 1988;242:1257-63.
19. Taubes G. Epidemiology faces its limits. Science 1995;269 164.
20. Siemiatycki J, Wacholder S, Dewar R et al. Smoking and degree of occupational exposure: Are internal analyses in cohort studies likely to be confounded by smoking status? Am J Ind Med 1988;13:59-69.
21. Pearce N, Beasley R, Crane J, Burgess C. Pharmacoepidemiology of asthma deaths. In: Tilson H (ed.). Pharmacoepidemiology: An Introduction. 3rd edn. Cincinattie OH: Harvey Whitney, 1998. pp. 473-94.
22. Nuland SB. Doctors: The biography. New York: Vintage, 1989.
23. Cochrane A. Horizon: The trouble with medicine. United Kingdom: BBC TV, 1976.
24. Law J. Big pharma: How the world's biggest drug companies control illness. London: Constable & Robinson, 2006.
25. Chren MM, Landefeld CS, Murray TH. Doctors, drug companies and gifts. JAMA 1989;262:3448-51.
26. Cafmey SL, Nair KR, Sales MA, Walsh J. Pharmaceutical industry-sponsored meetings: Good value or just a free meal? Intern Med J 2001;31 488-91.
27. Lexchin J. Interactions between Physicians and the pharmaceutical-industry what does the literature say. Can Med Assoc J 1993;149:1401-7.
28. Rutledge P, Crookes D, McKinstry B, Maxwell SRJ. Do doctors rely on pharmaceutical industry funding to attend conferences and do they perceive that this creates a bias in their drug selection? Results from a questionnaire survey. Pharmacoepidemiol Drug Saf 2003;12 663-67.
29. Wazana A. Physicians and the pharmaceutical industry - Is a gift ever just a gift? JAMA 2000;283:373-80.
30. Zipkin DA, Steinman MA. Interactions between pharmaceutical representatives and doctors in training. J Gen Intern Med 2005; 20:777-86.
31. Garner P, Kale R, Dickson R, Dans T, Salinas R. Implementing research findings in developing countries. Br Med J 1998;317:531-35.
32. Egilman DS. Suppression bias at the journal of occupational and environmental medicine. Int J Occup Environ Health 2005;11 202-4.
33. Friedman LS, Richter ED. Conflicts of interest and scientific integrity. Int J Occup Environ Health 2005;11:205-6.
34. Hardell L, Walker MJ, Walhjalt B, Friedman LS, Richter ED. Secret ties to industry and conflicting interests in cancer research. Am J Ind Med 2006;50:227-33.
35. Vedantam S. Science clash at medical journal. The Washington Post 2004; February 7th, 2004.
36. Greenland S. The need for critical appraisal of expert witnesses in epidemiology and statistics. Wake Forest Law Rev 2004;39 291-310.
37. Michaels D. Scientific evidence and public policy. Am J Public Health 2005;95:S5-S7.
38. Michaels D. Doubt is their product. Sci Am 2005;292:96-101.
39. Michaels D. Manufactured uncertainty - protecting public health in the age of contested science and product defense. Living in a Chemical World: Framing the Future in Light of the Past. Ann NY Acad Sci 2006; 1076:149-62.
40. Michaels D, Monforton C. Manufacturing uncertainty: Contested science and the protection of the public's health and environment. Am J Public Health 2005;99:S39-S48.
41. Boseley S. Renowned cancer scientist was paid by chemical firm for 20 years. The Guardian 2006 December 8th.
42. Infante PF. The past suppression of industry knowledge of the toxicity of benzene to humans and potential bias in future benzene research. Int. J Occup. Environ Health 2006;12:268-72.
43. Monforton C. Weight of the evidence or wait for the evidence? Protecting underground miners from diesel particulate matter. Am J Public Health 2006;96:271-76.
44. Michaels D, Monforton C, Lurie P. Selected science: An industry campaign to undermine an OSHA hexavalent chromium standard. Environ Health 2006;5:5.
45. Egilman D. Corporate corruption of science - the case of chromium(VI). Int J Occup Environ Health 2006;12:169-76.
46. Zhang JD, Li S. Cancer mortality in a Chinese population exposed to hexavalent chromium in water. J Occup Environ Med 1997;39 315-19.
47. Brandt-Rauf P. Editorial retraction. J Occup Environ Med 2006; 48:749.
48. Pearce N. The rise and rise of corporate epidemiology and the narrowing of epidemiology's vision. Int J Epidemiol. 2007;36:713-7.
49. Meier P. Damned lies and expert witnesses. J Am Stat Assoc 1986; 394:269-76.
50. Pearce N, Crawford-Brown D. Critical discussion in epidemiology: problems with the Popperian approach. J Clin Epidemiol 1989;42 177-84.
51. Barnes DE, Bero LA. Why review articles on the health effects of passive smoking reach different conclusions. J Am Med Assoc 1998;279 1566-70.
52. Stelfox HT, Chua G, O'Rourke K, Detsky AS. Conflict of interest in the debate over calcium-channel antagonists. New Ergl J Med 1998; 338:101-6.
53. Rothman KJ. Conflict of interest: The new McCarthyism in science. J Am Med Assoc 1993;269:2782-84.
54. Rothman KJ, Evans S. Extra scrutiny for industry funded trials - JAMA's demand for an additional hurdle is unfair - and absurd. Br Med J 2005;331:1350-51.
55. Anon. Asthma drug controversy climaxes with government decision to restrict use. Epidemiol Monitor 1990;11:1-5.
56. Michaels D, Bingham E, Boden L et al. Advice without dissent. Science 2002;298:703.
57. Clapp R, Hoppin P, Kriebel D. Erosion of the integrity of public health science in the USA. Occup Environ Med 2006;63:367-68.
58. Horton R. Vioxx, the implosion of Merck, and aftershocks at the FDA. Lancet 2004;364:1995-96.
59. Topol EJ. Failing the public health - Rofecoxib, Merck, and the FDA. N Engl J Med 2004;351:1707-9.
60. Last JM. Guidelines on ethics for epidemiologists. Int J Epidemiol 1990;19:226-29.
61. Neutra RR, Cohen A, Fletcher T, Michaels D, Richter ED, Soskolne CL. Toward guidelines for the ethical reanalysis and reinterpretation of another's research. Epidemiology 2006;17:335-38.
62. Prineas RJ, Goodman K, Soskolne CL et al. Findings from the American College of epidemiology's survey on ethics guidelines. Ann Epidemiol 1998;8:482-89.
63. Soskolne CL, Sieswerda LE. Implementing ethics in the professions: examples from environmental epidemiology. Sci Eng Ethics 2003;9 181-90.
64. Soskolne CL. Epidemiology: Questions of science, ethics, morality, and law. Am J Epidemiol 1989;129:1-18.
65. Olsen J. Good epidemiological practice: Proper conduct in epidemiologic research. International Epidemiological Association, 2007.
66. Davey Smith G. Reflections on the limitations to epidemiology. J Clin Epidemiol 2001;54:325-31.
67. Vallance P. Developing ans open relationship with the drug industry. The Lancet 2005;366:1062-64.